Why PRP and HA Are Not Covered by Insurance for Joint Pain
Insurance companies and HMOs do not cover PRP and hyaluronic acid injections for joint pain because major medical societies have issued strong recommendations against their use based on lack of proven efficacy, concerns about standardization, and insufficient evidence of meaningful clinical benefit.
The Evidence-Based Rationale
PRP (Platelet-Rich Plasma)
The American College of Rheumatology/Arthritis Foundation strongly recommends against PRP for knee and hip osteoarthritis 111. The primary concerns are:
- Lack of standardization: There is significant heterogeneity in PRP preparations and techniques, making it impossible to identify exactly what is being injected 11
- Inconsistent evidence: While some studies show benefit, the evidence is mixed and unreliable 2
- Cost and safety concerns: The treatment is expensive with unclear safety profiles 2
The 2020 VA/DoD guidelines could not recommend for or against PRP due to inconsistent study results 333. Even the 2022 AAOS guideline, which found some supporting evidence (2 high-quality and 1 moderate-quality study), noted that PRP showed worse treatment response in patients with severe knee osteoarthritis 2.
Hyaluronic Acid (HA)
The evidence against HA is even more definitive:
- Conditionally recommended against for knee OA and strongly recommended against for hip OA by the ACR/Arthritis Foundation 14111
- Critical finding: When limited to low-risk-of-bias trials, the effect size of HA compared to saline injections approaches zero 1411
- The apparent benefits seen in earlier reviews were restricted to studies with higher risk of bias 11
The AAOS 2022 guideline recommended against routine use of HA, noting that while the calculated number needed to treat was 17 patients, the evidence does not identify which subset of patients might benefit 2.
The Insurance Coverage Logic
Insurance companies base coverage decisions on:
- Evidence of efficacy: Both treatments lack consistent, high-quality evidence of meaningful clinical benefit
- Professional society recommendations: When the American College of Rheumatology, AAOS, and VA/DoD all recommend against or cannot support these treatments, insurers follow suit
- Cost-effectiveness: PRP costs range from $350-$2,815 per injection 5, with no proven superiority over less expensive alternatives like corticosteroid injections
- Standardization concerns: The lack of FDA regulation and standardized preparations means insurers cannot ensure consistent product quality 21
Important Nuances
The ACR guideline explicitly states: "The conditional recommendation against is not intended to influence insurance coverage decisions" 14. This acknowledges that some clinicians may choose to use HA in shared decision-making when other treatments have failed, recognizing the contextual effects of intra-articular injections 111.
However, this statement reflects clinical flexibility, not evidence of efficacy. Insurance companies appropriately prioritize treatments with proven benefit for coverage decisions.
What Actually Works
Evidence-based alternatives that ARE typically covered include:
- Weight loss for overweight/obese patients (strong evidence) 2
- Physical therapy and exercise (clear evidence of benefit) 333
- Oral NSAIDs (consistent improvement in pain and function) 2
- Intra-articular corticosteroids (19 high-quality studies supporting use, though benefits last ~3 months) 233
Common Pitfalls
Patients often pursue PRP and HA because:
- Direct-to-consumer marketing creates unrealistic expectations 6
- They are desperate for alternatives to surgery
- They misunderstand that "biologic" means "proven effective"
The reality is that lack of insurance coverage reflects lack of evidence, not insurance company greed. When treatments demonstrate clear benefit (like corticosteroid injections), they receive coverage.